- Home
- CYCC
as 05-05-2025 4:00pm EST
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.
| Founded: | 1992 | Country: | Malaysia |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 47.6M | IPO Year: | N/A |
| Target Price: | $11.00 | AVG Volume (30 days): | 7.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | -2.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.17 - $4.00 | Next Earning Date: | 05-13-2025 |
| Revenue: | $43,000 | Revenue Growth: | -89.76% |
| Revenue Growth (this year): | 137.21% | Revenue Growth (next year): | N/A |
Latest Cyclacel Pharmaceuticals Inc. News
CYCC Breaking Stock News: Dive into CYCC Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
GlobeNewswire
a month ago
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
GlobeNewswire
2 months ago
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
MT Newswires
4 months ago
Cyclacel Pharmaceuticals Says David Lazar Buys $3.1 Million in Preferred Stock, Becomes Interim CEO
GlobeNewswire
4 months ago
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
GlobeNewswire
5 months ago
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
Simply Wall St.
6 months ago
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
GlobeNewswire
6 months ago
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Compare CYCC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYCC Cyclacel Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.